Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 10 Days Inventory is 2,407.56 as of May. 2026, which is 2636% above its 10-year median of 87.99. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €0.94 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Heidelberg Pharma AG ranks worse than 98.28% on this metric.
The historical rank and industry rank for Heidelberg Pharma AG's Days Inventory or its related term are showing as below:
WBO:HPHA'
s Days Inventory Range Over the Past 10 Years
Min: 15.25 Med: 87.99 Max: 13637.18
Current: 7285.84
During the past 13 years, Heidelberg Pharma AG's highest Days Inventory was 13637.18. The lowest was 15.25. And the median was 87.99.
WBO:HPHA's Days Inventory is ranked worse than 98.28% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs WBO:HPHA: 7285.84
Heidelberg Pharma AG's Days Inventory
declined
from May. 2025 (22,150.94) to May. 2026 (2,407.56).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Heidelberg Pharma AG's Inventory Turnover for the
three
months ended in May. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Heidelberg Pharma AG's Inventory-to-Revenue for the
three
months ended in May. 2026 was 2.31.
Heidelberg Pharma AG (WBO:HPHA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Heidelberg Pharma AG's Inventory Turnover for the
three
months ended in May. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Heidelberg Pharma AG's Inventory to Revenue for the
three
months ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Heidelberg Pharma AG Days Inventory Related Terms
Heidelberg Pharma AG Days Inventory Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HPHA vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Days Inventory distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (WBO:HPHA) has a Days Inventory of 2,407.56 as of May. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Heidelberg Pharma AG and its competitors. This is 2636% above median its historical median of 87.99. Over the past decade, Heidelberg Pharma AG's Days Inventory has ranged from 15.25 to 13,637.18. According to the industry distribution chart, Heidelberg Pharma AG ranks #627 out of 638 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Heidelberg Pharma AG's Days Inventory too high?
Heidelberg Pharma AG's current Days Inventory of 2,407.56 is 2636% above median its 10-year median of 87.99. Over the past 10 years, this metric has ranged from a low of 15.25 to a high of 13,637.18. The Biotechnology industry median Days Inventory is 183.20. Heidelberg Pharma AG's value of 2,407.56 is 1214.2% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #627 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #627 out of 638 companies for Days Inventory. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Days Inventory is 183.20. Heidelberg Pharma AG's value of 2,407.56 is 1214.2% above this benchmark. Historically, Heidelberg Pharma AG's own Days Inventory has ranged from 15.25 to 13,637.18 over the past decade. While the company's 10-year median is 87.99 vs. the industry median of 183.20, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Days Inventory of 2,407.56 is 1214.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Days Inventory is 2,407.56, which is 2636% above median its own 10-year median of 87.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.94, compared to a current price of €2.55 — trading 171.3% above its estimated fair value. The current Days Inventory is 2,407.56, which is 2636% above median its 10-year median of 87.99 and 1214.2% above the Biotechnology industry median of 183.20. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Days Inventory is 2,407.56 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 171.3% above its estimated GF Value™ of €0.94.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for WBO:HPHA:
Days Inventory: 2,407.56 (2636% above median its 10-year median of 87.99)
GF Value™: €0.94 vs. price of €2.55 (171.3% above fair value)
Industry Position: 1214.2% above the Biotechnology median (#627 of 638)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
